Focusing on the proximal promoter region of ctgf/ccn2 (Figure 3A), we tested the impact of T. cruzi PCM treatment on basal and TGF-ß stimulated reporter activity using a series of ctgf/ccn2 promoter/SEAP reporter plasmids [21], [27] transfected into human dermal fibroblasts. The gene discussed is CCN2; the disease is paracoccidioidomycosis.